Menthone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Menthone is a medication used to treat stone formation in the gallbladder and liver.

Generic Name
Menthone
DrugBank Accession Number
DB15920
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 154.253
Monoisotopic: 154.1357652
Chemical Formula
C10H18O
Synonyms
  • DL-Menthone
  • Menthone G
External IDs
  • 201-941-1

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ROWACHOL CAPSULESMenthone (6 mg) + Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + Olive oil (33 mg) + alpha-Pinene (17 mg)CapsuleOralDCH AURIGA (MALAYSIA) SDN. BHD.2020-09-08Not applicableMalaysia flag
โรวาคอลMenthone (6 mg) + Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + alpha-Pinene (13.6 mg) + beta-Pinene (3.4 mg)Capsuleบริษัท ดีซีเอช ออริกา (ประเทศไทย) จำกัด1986-09-25Not applicableThailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9NH5J4V8FN
CAS number
89-80-5
InChI Key
NFLGAXVYCFJBMK-UHFFFAOYSA-N
InChI
InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-9H,4-6H2,1-3H3
IUPAC Name
5-methyl-2-(propan-2-yl)cyclohexan-1-one
SMILES
CC(C)C1CCC(C)CC1=O

References

General References
  1. FDA Thailand: Rowachol (Borneol, Camphene, Eucalyptol, Levomenthol, Menthone, Alpha-Pinene, and Beta-Pinene) Oral Capsule [Link]
ChemSpider
6720
ChEBI
36742
ChEMBL
CHEMBL1719455
Wikipedia
Menthone

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Capsule
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.265 mg/mLALOGPS
logP2.65ALOGPS
logP3.05Chemaxon
logS-2.8ALOGPS
pKa (Strongest Basic)-7.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area17.07 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity46.52 m3·mol-1Chemaxon
Polarizability19.02 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01qj-9700000000-c156de7fc6eaf5b509ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-40e722548ee3d085ed47
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-af2a05129ae121f567d1
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000b-9200000000-d1639dfcec62e7ab91c9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gbi-3900000000-3648b9f5ae05b0b1f18f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0536-9200000000-c645d88846ee2e239afa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-137.1037801
predicted
DarkChem Lite v0.1.0
[M-H]-132.42752
predicted
DeepCCS 1.0 (2019)
[M+H]+138.0210801
predicted
DarkChem Lite v0.1.0
[M+H]+136.23584
predicted
DeepCCS 1.0 (2019)
[M+Na]+137.2268801
predicted
DarkChem Lite v0.1.0
[M+Na]+144.9026
predicted
DeepCCS 1.0 (2019)

Drug created at November 23, 2020 16:18 / Updated at May 07, 2021 21:08